



Press release, January 22, 2016

Diamyd Medical CEO proposed as new Chairman for Cellaviva AB

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that its CEO, Anders Essen-Möller is proposed as new Chairman of the Board of Cellaviva AB at Cellaviva's Annual General Meeting, February 18, 2016. Diamyd Medical is the largest shareholder of Cellaviva AB, Sweden's first biobank for family saving and research on stem cells from the umbilical cord.

"The umbilical cord contains stem cells that can be differentiated into several of the various cells of the body. This technology is one of today's fastest growing medical research areas and Diamyd Medical's commitment is primarily due to its interest in regenerative medicine, particularly within the field of type 1 diabetes," says Anders Essen-Möller, President and CEO of Diamyd Medical. "Many other, and perhaps sooner applications may become available and transplantation of autologous stem cells may then be a treatment alternative in several situations. It is with excitement that I look forward to get the possibility to influence on this development and in particular to what I can do for Cellaviva's research-bank that is now being established and to which it will be possible to donate stem cells from the umbilical cord."

The reference below from 2015 gives an overview of the development of stem cells from so called Wharton's jelly, present in the umbilical cord.

Wharton's jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance. Kalaszczynska I, Ferdyn K. Biomed Res Int. 2015
<http://www.ncbi.nlm.nih.gov/pubmed/25861624>

About Cellaviva AB

Cellaviva is Sweden's first biobank for family saving of and research on stem cells from the umbilical cord. Stem cells from the umbilical cord are collected at birth, analyzed, frozen, and saved for possible future use. Every cell in the body is stemming from stem cells that have unique properties, which make them attractive from a medical perspective. The operations work under approval from the Swedish Health and Social Care Inspectorate (IVO). Read more at www.cellaviva.se.

About Diamyd Medical

Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd[®], an Antigen Based Therapy (ABT) based on the exclusively licensed GAD-molecule. The Company's licensed technologies for GABA and Gliadin have also potential to become key pieces of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes, and also certain inflammatory diseases. At this time six clinical studies are ongoing with Diamyd[®]. Diamyd Medical is with its holdings of 39% one of the major shareholders in the stem cell company Cellaviva AB. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example for restoration of beta cell mass in diabetes patients where the autoimmune component of the disease has been arrested. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical's B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company's Certified Adviser.

For further information, please contact:

Anders Essen-Möller, President and CEO, Diamyd Medical AB
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com

Mathias Svahn, CEO Cellaviva AB
Phone: +46 702 61 55 04. E-mail: mathias.svahn@cellaviva.se

Diamyd Medical AB (publ)

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.